BNT327, now in early-phase trials, is part of a class of drugs that could one day challenge Keytruda’s dominance. BioNTech ...

Disease progression eventually occurs in many patients that were included in these trials, raising the issue that undiscovered pathways mediate angiogenic escape after VEGF inhibition. Different ...

These findings suggest that, although VEGF signaling may be a rate-limiting step in a wide variety of circumstances, local regulatory pathways modulate endothelial-cell growth and function in a ...

Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. Check out my recommendation for TIL stock.

Sequential therapy with either continued VEGF receptor inhibition (tyrosine kinase inhibitor [TKI]-TKI sequence) or alternate pathway inhibition (TKI–mTOR sequence) results in prolonged disease ...

BNT327/PM8002 works by blocking the PD-L1 pathway and neutralizing VEGF-A, resulting in anti-tumor immune responses. Keytruda, on the other hand, only targets the PD-L1 pathway to boost the immune ...

Conventional anti-VEGF therapies primarily target immature blood vessels in tumors. The combinational targeting of both ANGPT2 and VEGF pathways is now expected to improve clinical efficacy by ...

Whereas Keytruda is a monoclonal antibody that targets only the PD-L1 pathway to trigger the immune system to attack cancer cells, bispecific antibodies like LM-299 target both the PD-1 and VEGF ...